

Date: 30.05.2022

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Submission of Audited Financial Results for the Quarter and Year ended on March 31, 2022 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. May 30, 2022, inter alia, considered and approved followings:

1. Audited Financial Results for the quarter and financial year ended March 31, 2022 along with Auditor's Report.

A copy of the Audited Financial Results of the Company for the quarter and year ended March 31, 2022 along with statements of Assets & Liabilities, Cash Flow Statement, Auditors' Report and declaration on Audit Reports with unmodified opinion are enclosed as Annexure-A.

2. The Board of Directors of the Company on recommendation of Audit Committee, has subject to the approval of the Shareholders at the ensuing 37th Annual General Meeting of the Company (AGM), approved the appointment of M/s. CNK & Associates LLP, (Firm Registration No. 101961WW-100036), Chartered Accountants, Vadodara, as the Statutory Auditors of the Company for a period of 5 (five) years from the conclusion of ensuing 37th Annual General Meeting (AGM) of the Company to be held in the year 2022 till the conclusion of 42nd AGM to be held in the year 2027, in place of the existing Statutory Auditors, M/s. Sanjay Soni & Associates, Chartered Accountants whose term of five years would conclude at the ensuing 37th Annual General Meeting of the Company. The particulars for appointment of M/s. CNK & Associates LLP, Chartered Accountants, as Statutory Auditors of the Company are enclosed as Annexure-B.



The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 02:30 p.m.

We shall inform you in due course the date on which the Company will hold its Annual General Meeting for the year ended March 31, 2022.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For Link Pharma Chem Limited

Bhushan Joshi

Bhushan Joshi
Company Secretary



Encl: As above.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

(In Rs. Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	1128.95	1402.76	1124.27	5,356.06	3481.26
	Other income	(1.08)	32.09	2.15	46.44	2.15
	Total Income (A)	1127.87	1434.85	1126.42	5,402.50	3483.41
2	Expenses:					
	Cost of materials consumed	875.59	978.55	676.89	3,788.63	1793.26
	Changes in inventories of finished goods and work-in-progress	(116.05)	20.58	9.53	(145.46)	(15.59)
	Employee benefits expense	192.33	145.90	151.00	577.26	562.86
	Finance costs	4.44	15.64	10.74	45.12	44.04
	Depreciation and amortization expense	27.23	21.85	17.81	92.78	87.40
	Other Expenses	111.74	153.54	223.87	782.01	843.59
	Total expenses (B)	1095.28	1336.06	1089.84	5,140.34	3315.56
3	Profit before tax (C) = (A-B)	32.59	98.79	36.58	262.16	167.85
4	Tax expense:					
	(1) Current tax	16.05	28.59	13.74	74.13	38.51
	(2) MAT credit recognised	-	-	10.55	-	25.55
	(3) Short/(Excess) Provision of tax relating to earlier Year	(7.46)	-	-	(7.46)	-
	(3) Deferred tax	(3.37)	-	(3.33)	7.32	(4.70)
	Total tax expense (D)	5.22	28.59	20.96	73.99	59.36
5	Profit for the year (E) = (C-D)	27.37	70.20	15.62	188.17	108.49
6	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss	2.43	-	3.06	5.43	6.06
	Income tax effect on above	(1.59)	-	(1.19)	(2.19)	(1.79)
	Total other comprehensive income for the year, net of tax (F)	0.84	-	1.87	3.24	4.27
7	Total comprehensive income for the year (Net of Tax) (E)+(F)	28.21	70.20	17.49	191.41	112.76
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06
	Earnings per equity share (FV of Rs. 10) (Rs.)					
	Basic and Diluted	0.62	1.58	0.35	4.24	2.44
	See accompanying notes to the Financial Results					



NOTES:

- 1 These Financial Results were reviewed by Audit Committee and approved by Board of Directors in their respective meeting held on 30th May, 2022
- 2 The Company's operations fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind AS 108) on Segment Reporting.
- 3 The Company has evaluated the Impact of COVID - 19 on its financial statements based on the internal and external information upto the date of approval of these financial statements and expect to recover the carrying amount of inventories, receivables and investments. The Company does not foresee material impact on liquidity and assumption of going concern.
- 4 The figures of the last quarter of the current year and of the previous year are the balancing figures between the audited figures for the full financial year and the published year to date figures up to third quarter of the respective financial years. Also, the figures for each of the quarter upto the end of the third quarter had only been subjected to a limited review and not subjected to audit.
- 5 Previous period/year figures have been regrouped and/ or re-arranged wherever necessary to make their classification comparable with the current period/year.

Date : 30th May, 2022

Place : Vadodara



For Link Pharma Chem Limited

Satish G. Thakur
Chairman & Wholetime Director
(DIN : 00292129)

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2022

Particulars	Audited As at March 31, 2022	Audited As at March 31, 2021
I. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	878.54	870.63
(b) Capital work in progress	21.13	-
(c) Financial Assets		
(i) Investments	451.92	3.30
(ii) Other financial assets	73.04	64.90
(e) Other non-current assets	114.13	150.73
Total non-current assets	1,538.76	1,089.56
2. CURRENT ASSETS		
(a) Inventories	475.72	249.66
(b) Financial Assets		
(i) Trade receivables	536.51	555.14
(ii) Cash and cash equivalents	26.79	422.21
(iii) Bank Balances other than (ii) above	61.55	63.48
(iv) Loans	4.12	5.10
(v) Other financial assets	5.28	3.56
(c) Current Tax assets (Net)	-	2.63
(d) Other Current Assets	247.67	212.70
Total current assets	1,357.64	1,514.48
Total Assets	2,896.40	2,604.04
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	444.05	444.06
(b) Other equity	1,003.42	812.00
Total Equity	1,447.47	1,256.06
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
- Borrowings	290.16	316.30
(b) Provisions	3.46	17.16
(c) Deferred tax liabilities (Net)	94.05	86.67
Total non-current liabilities	387.67	420.13
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	348.64	50.14
(ii) Trade payables	-	-
- Total outstanding dues of MSME	51.35	0.92
- Total outstanding dues to other creditors	426.17	683.69
(ii) Other financial liabilities	7.10	8.64
(b) Other Current Liabilities	214.35	169.52
(c) Current Tax liabilities (Net)	13.65	14.94
Total current liabilities	1,061.26	927.85
Total Equity and liabilities	2,896.40	2,604.04

Figures for the previous year have been rearranged /reclassified wherever necessary, to correspond with current period/year presentation.

For Link Pharma Chem Limited

Date : 30th May, 2022
Place : Vadodara



Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2022

Particulars	(In Rs. Lakhs)	
	For the year ended March 31, 2022	For the year ended March 31, 2021
A. Cash Flow From Operating Activities		
Net profit before taxation	262.17	167.84
Adjustments For :		
Depreciation and amortization expense	92.78	87.40
Net gain on sale of investments	(51.60)	
Net Gains (losses) on fair value changes of Investments designated at FVTPL	29.69	
Loss / (Profit) on Sale of Property, Plant & Equipment	(11.80)	16.35
Interest income	(11.01)	(1.65)
Finance cost	45.12	44.04
Net Adjustments	93.18	146.14
Operating Profit Before Working Capital Changes	355.35	313.98
Adjustments For :		
(Increase)/Decrease in inventories	(226.06)	(86.54)
(Increase)/Decrease in trade receivables	18.64	(55.73)
(Increase)/Decrease in financial assets	0.65	(32.37)
(Increase)/Decrease in other assets	(34.97)	(89.72)
Increase/(Decrease) in trade and other payables	(171.25)	482.43
Working Capital Changes	(412.99)	218.07
Cash Generated From Operations	(57.64)	532.05
Taxes Paid (Net)	(67.46)	(47.60)
Net Cash From Operating Activities	(125.10)	484.45
B. Cash Flow From Investing Activities		
Purchase of property, plant & equipment	(115.56)	(180.58)
Proceeds from sale of property, plant & equipment	41.10	10.25
Purchase of Investments	(478.10)	-
Proceeds from sale of Investments	51.60	-
Proceeds from maturity of bank deposits	(5.89)	(45.27)
Interest received	9.28	(0.66)
Net Cash Used in Investing Activities	(497.57)	(216.26)
C. Cash Flow From Financing Activities		
Proceeds from borrowings	13.95	149.78
Repayment of borrowings	258.43	(138.77)
Finance cost paid	(45.12)	(44.04)
Net Cash Used In Financing Activities	227.26	(33.03)
Net Increase In Cash and Cash Equivalents (A+B+C)	(395.41)	235.16
Cash and Cash Equivalents at Beginning of Year	422.20	187.04
Cash and Cash Equivalents at the End of Year	26.79	422.20

Date : 30th May, 2022
Place : Vadodara



For Link Pharma Chem Limited

[Signature]
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)



Link

Pharma Chem Ltd.

ISO-9001 - 2015

ISO-14001 - 2015

REGISTERED OFFICE :

Plot No. 161/1, 162, G.I.D.C.,

Nandesari - 391340,

Dist. Baroda (Gujarat) (India)

Tel. (O) (0265) 2840281 / 2840282

E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540

DECLARATION

Declaration pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on Audit Report with unmodified opinion

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that, M/s. Sanjay Soni & Associates, Chartered Accountants, (FRN: 113251W) Statutory Auditor of the Company have issued an Audit Report with unmodified opinion and contains no qualification or adverse remark on the Standalone Audited Financial Results of the Company for the financial year ended on March 31, 2022.



For Link Pharma Chem Limited

Date: 30.05.2022

Place: Vadodara

Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)



S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.
(O) : 0265-2983872, (M) : 98254 83162, E-mail : sanjayseni@gmail.com

Independent Auditor's Report on Annual Financial Results and Year to Date Financial Results of Link Pharma Chem Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended.

TO THE BOARD OF DIRECTORS OF
LINK PHARMA LIMITED

Report on the audit of the Financial Results

Opinion

We have audited the accompanying financial results of Link Pharma Chem Ltd (hereinafter referred to as 'the company') for the year ended March 31, 2022 ('the statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended ('Listing Regulation').

In our opinion and to the best of our information and according to the explanation given to us, the aforesaid statement:

- I. Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- II. Gives a true and fair view in conformity with the recognition and measurement principle laid down in the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('the Act') read with Companies (Indian Accounting standards) Rules, 2015, as amended, and other accounting principle generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2022 and statement of assets and liabilities and the statement of cashflows as at and for the year ended on that date.


Basis for Opinion

We conducted our audit in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the company in accordance with code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Acts and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the annual financial results.

Board of Director's Responsibilities for the Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of company and the statement of assets and liabilities and statements of cashflows in accordance with the recognition and measurements principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued there under and other accounting principle generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for the maintenance of adequate



Sanjay Soni & Associates

Chartered Accountants

....contd

accounting records in accordance with the provision of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities ; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the statement by Directors of the Company, as aforesaid.

In preparing the statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operation, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible of overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risk of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentation, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosure made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as going concern.



Sanjay Soni & Associates

Chartered Accountants

....contd.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves, fair presentation.

We communicate with those charged with governance of the company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit finding, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirement regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Materiality is the magnitude of misstatements in the standalone financial results that individually or in aggregate, make it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider qualitative materiality and quantitative factors in (i) planning the scope of our audit work and in evaluating the results of our work : and(ii) to evaluate the effect of any indentified misstatement in the annual financial results.

Other Matters

The statements includes the results for the quarter ended March 31, 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standard 34 'Interim Financial Reporting', which were subject to limited review by us.

For Sanjay Soni & Associates

Chartered Accountants

ICAI Firm Registration No.: 113251W



Sanjay Soni

Partner

Membership No.: 040616

UDIN: 22040616AJVXIC4188

Place: Vadodara



Date: May 30, 2022

Annexure B

The details required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are as below:

Sr. No.	Particulars	
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	<p>Appointment.</p> <p>The first term of five consecutive years would conclude at the ensuing 37th Annual General Meeting of the Company as per Section 139(2) of Companies Act, 2013 of present Statutory Auditors M/s. Sanjay Soni & Associates, Chartered Accountants, Vadodara. The Board of Directors on recommendation of Audit Committee has appointed M/s. CNK & Associates LLP, Chartered Accountant for the first term of five years commencing from the conclusion of ensuing 37th Annual General Meeting, till the conclusion of the 42nd Annual General Meeting of the Company, which shall be subject to the approval of the Shareholders.</p>
2.	Date of appointment/cessation (as applicable) & term of appointment	<p>Ensuing 37th Annual General Meeting of the Company.</p> <p>Appointed for the first term of five consecutive years commencing from the conclusion of ensuing 37th Annual General Meeting of the Company, till the conclusion of the 42nd Annual General Meeting of the Company to be held in year 2027, which shall be subject to the approval of the Shareholders.</p>
3.	Brief Profile	<p>CNK & Associates LLP (CNK) is a multi-disciplinary firm specializing in providing a wide spectrum of professional services under one roof to leading domestic and multinational corporations, spread across virtually all sectors.</p> <p>CNK is registered with The Institute of Chartered Accountants of India ("ICAI") with Firm Registration No. 101961W /W-100036.</p> <p>The firm has its presence in Mumbai, Bangalore, Chennai, Vadodara, Ahmedabad, Gandhinagar, Delhi, Dubai and Sharjah. The firm has been subjected to peer review process by the Institute of Chartered Accountants of India and has received a Certificate of Peer Review.</p>
4.	Disclosure of relationship between Directors (in case of appointment of a director)	Not applicable

